HuGE Literature Finder
Records
1
-
3
Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer. Pharmacological research 2017 Aug . Lam Siu W, van der Noort Vincent, van der Straaten Tahar, Honkoop Aafke H, Peters Godefridus J, Guchelaarc Henk-Jan, Boven Ep |
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Apr 17 (7): 2006-13. Caronia Daniela, Martin Miguel, Sastre Javier, de la Torre Julio, García-Sáenz José Angel, Alonso Maria R, Moreno Leticia T, Pita Guillermo, Díaz-Rubio Eduardo, Benítez Javier, González-Neira An |
A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. Current drug metabolism 2008 May 9 (4): 336-43. Ribelles N, López-Siles J, Sánchez A, González E, Sánchez M J, Carabantes F, Sánchez-Rovira P, Márquez A, Dueñas R, Sevilla I, Alba |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jun 27, 2022
- Content source: